{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:09:43Z","timestamp":1793426983360,"version":"4.5.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      The aims of this study were to report an exceptionally rare case of\n                      <jats:italic>de novo<\/jats:italic>\n                      small cell neuroendocrine carcinoma of the prostate (SCNEPC) presenting with unprecedented prostate-specific antigen (PSA) elevation and Gleason score 5 + 5, and to describe the remarkable treatment response achieved with multimodal therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>A 72-year-old man presented with PSA 982 ng\/mL and extensive skeletal metastases. Prostate biopsy revealed mixed histology comprising small cell neuroendocrine carcinoma (Gleason 5 + 5 = 10) in seven cores and adenocarcinoma (Gleason 5 + 4 = 9) in three cores (T3bN1M1). The patient received six cycles of cisplatin\u2013etoposide chemotherapy combined with goserelin and apalutamide. Post-treatment evaluation demonstrated profound biochemical response with PSA declining to 0.90 ng\/mL (99.9% reduction), pro-gastrin-releasing peptide (ProGRP) decreasing to 75.7 pg\/mL, and testosterone suppressed to castrate levels. Imaging confirmed substantial lesion regression with no new metastases. The patient experienced dramatic clinical improvement and remains alive with controlled disease under ongoing androgen deprivation therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This represents the first reported case of\n                      <jats:italic>de novo<\/jats:italic>\n                      SCNEPC with Gleason score 5 + 5, demonstrating that intensive multimodal therapy combining platinum-based chemotherapy with contemporary androgen receptor pathway inhibition can achieve profound and sustained responses in this aggressive variant typically associated with dismal outcomes. The substantial adenocarcinoma component may have contributed to the exceptional treatment response.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1741030","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:27Z","timestamp":1767331467000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["De novo small cell neuroendocrine carcinoma of the prostate with extremely elevated PSA and Gleason score 5 + 5: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Yiwen","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.04.006","article-title":"Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis","volume":"15","author":"Zaffuto","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200606000-00005","article-title":"Small cell carcinoma of the prostate: an immunohistochemical study","volume":"30","author":"Yao","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000020289","article-title":"Low PSA metastatic androgen-independent prostate cancer","volume":"38","author":"Sella","year":"2000","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.02.006","article-title":"Comparison of typical prostate adenocarcinoma and rare histological variant prostate cancer showed different characteristics and prognosis: a SEER database analysis","volume":"82","author":"Zhou","year":"2022","journal-title":"Eur Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2012.4","article-title":"A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008","volume":"15","author":"Marcus","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.07.082","article-title":"The risk of distant metastases and cancer specific survival in men with serum prostate specific antigen values above 100 ng\/ml","volume":"194","author":"Stattin","year":"2015","journal-title":"J Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228447","article-title":"Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason grade: nationwide, population-based register study","volume":"15","author":"Thomsen","year":"2020","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.03.010","article-title":"Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: implications for managing patients upstaged on prostate magnetic resonance imaging","volume":"33","author":"Nezolosky","year":"2015","journal-title":"Urol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.05.056","article-title":"Adenocarcinoma of the prostate with Gleason score 9\u201310 on core biopsy: correlation with findings at radical prostatectomy and prognosis","volume":"190","author":"Ellis","year":"2013","journal-title":"J Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.11.006","article-title":"New prostate cancer grading system predicts long-term survival following surgery for Gleason score 8\u201310 prostate cancer","volume":"71","author":"Ham","year":"2017","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.03.015","article-title":"Salvage radical prostatectomy: baseline prostate cancer characteristics and survival across SEER registries","volume":"19","author":"Wenzel","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"zttard","year":"2022","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24189","article-title":"Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: a single institution experience","volume":"81","author":"Wee","year":"2021","journal-title":"Prostate"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V","article-title":"Treatment with cisplatin and etoposide in patients with neuroendocrine tumors","volume":"92","author":"Fj\u00e4llskog","year":"2001","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1741030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T05:24:28Z","timestamp":1767331468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1741030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":19,"alternative-id":["10.3389\/fonc.2025.1741030"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1741030","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1741030"}}